Instil Bio, Inc.
Instil Bio, Inc. (Nasdaq: TIL) is a biotechnology company focused on identifying and advancing therapeutic opportunities. It is currently seeking to in-license or acquire novel therapeutic candidates for diseases with significant unmet medical need and does not have a product candidate in active development. In… From the company’s description.
In fiscal 2025, Instil Bio, Inc. reported revenue of $8.97M, up 110.2% from fiscal 2024, and a net loss of $71.37M. Its operating margin was −876.2%, and operations used $36.62M in cash. Over the twelve months to Jun 30, 2026, revenue was $8.97M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Instil Bio, Inc. does
In the company’s own words
Instil Bio, Inc. (Nasdaq: TIL) is a biotechnology company focused on identifying and advancing therapeutic opportunities. It is currently seeking to in-license or acquire novel therapeutic candidates for diseases with significant unmet medical need and does not have a product candidate in active development. In January 2026, its wholly owned subsidiary Axion Bio discontinued development of AXN-2510, a bispecific antibody targeting programmed death-ligand 1 and vascular endothelial growth factors for solid tumors; the license and collaboration agreement for the candidate was terminated that month. Before pursuing AXN-2510, Instil focused on cell therapies, including its proprietary folate receptor alpha CoStAR tumor-infiltrating lymphocyte therapy for cancer. The company’s strategy centers on potential acquisitions and licensing arrangements rather than commercial products or services. Its business is organized around the biotechnology company’s therapeutic opportunity sourcing and development activities, with no reportable segments described here. The filing text provided does not state a corporate website.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- DALLAS, TX
- Fiscal year end
- December
- CIK
- 1789769
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Instil Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Instil Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Instil Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Instil Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Instil Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”